Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 28 of 30

TERMINATED Phase 1

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

NCT00337376

TERMINATED Phase 2

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

NCT00402662

COMPLETED Phase 2

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

NCT00699556

COMPLETED NA

The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

NCT00589134

COMPLETED Phase 1

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897

COMPLETED Phase 1

Studies on Aldosterone and Vascular Function

NCT00700479

TERMINATED

Vascular Effects of Sertraline in Heart Failure

NCT00585455

COMPLETED Phase 2

Craving, Binge Eating and Obesity

NCT00414167

COMPLETED NA

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

NCT00611767

COMPLETED NA

High-dose Periop Statins for Prevention of DVT

NCT00259662

COMPLETED NA

Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00293397

COMPLETED Phase 2

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

NCT00337987

COMPLETED NA

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335

COMPLETED Phase 1

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

NCT00338494

COMPLETED NA

Levetiracetam in the Management of Bipolar Depression

NCT00566150

COMPLETED Phase 1

Culturally Responsive Person-Centered Care for Psychosis

NCT00231933

COMPLETED Phase 2

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238

COMPLETED Phase 1

Evaluation of the Child and Family Traumatic Stress Intervention

NCT01031615

COMPLETED Phase 2

Enhancing Emergency Practitioner (EP)-Performed Alcohol Interventions in the Emergency Department (ED)

NCT00261859

TERMINATED Phase 1

Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension

NCT00237783

TERMINATED NA

Bariatric Surgery for ESRD Patients vs Control

NCT00580762

COMPLETED Phase 4

Buprenorphine and Integrated HIV Care

NCT00317460

COMPLETED

Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death

NCT00580775

COMPLETED Phase 2

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879

COMPLETED Phase 4

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

NCT00798538

COMPLETED Phase 2

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCT00420498

COMPLETED

FMRI of Stress and Addictive Disorders

NCT01558973

COMPLETED Phase 4

Counseling for Primary Care Office-based Buprenorphine

NCT00595764

COMPLETED NA

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

NCT00727740

COMPLETED

Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM

NCT00575783

COMPLETED NA

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

NCT00592072

COMPLETED

Neural, Behavioral and Physiological Correlates of Feeding in Humans

NCT01665560

COMPLETED

Microvascular Reactivity.

NCT00259701

COMPLETED

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243

COMPLETED Phase 1

CBT With Disulfiram and Contingency Management

NCT00350870

COMPLETED Phase 4

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

NCT00224289

COMPLETED

Validation of the Gated Blood Pool SPECT: ERNA vs 3D Echo

NCT00576186

COMPLETED Phase 3

Insulin Resistance Intervention After Stroke Trial

NCT00091949

COMPLETED NA

Use Ear Acupuncture as Treatment for Low Back Pain During Pregnancy

NCT00571480

COMPLETED Phase 1

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975

COMPLETED Phase 2

Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1

NCT00142909

COMPLETED Phase 2

Targeted Interventions for Weight-Concerned Smokers

NCT00105482

COMPLETED Phase 4

The Effect of Protein on Calcium Absorption and Gastric Acid Production

NCT00719160

COMPLETED NA

Ultrasound Study of the Uterine Healing Process After Cesarean Delivery

NCT00224250

COMPLETED Phase 1

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

NCT00129246

COMPLETED

Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents

NCT00272233

COMPLETED Phase 2

Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management

NCT00350649

COMPLETED Phase 2

Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack

NCT00251290

COMPLETED Phase 1

Brief Interventions for Drop-out Re-engagement

NCT00350571

COMPLETED Phase 2

Continuous Positive Airway Pressure for the Treatment of Stroke

NCT00368628

← Previous Page 28 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.